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Abstract
Background: Receptor activity modifying protein-1 (RAMP-1) is a single transmembrane-domain
protein required for the functional expression of calcitonin gene-related peptide (CGRP)
receptors. To date, little is known about the molecular mechanism(s) that activate/inhibit RAMP-1
gene expression. Such mechanism(s) are likely to play a major role in modulating the
responsiveness of tissues to CGRP.
Results: To initiate studies on the transcriptional regulation of the mouse RAMP-1 gene, RAMP-
1 transcriptional initiation sites were mapped in a variety of tissues. Analysis of RAMP-1 expression
in C2C12 myoblasts demonstrated that RAMP-1 mRNA is expressed at greatest levels in confluent
myoblasts verses non-confluent and fused myoblasts. Transfection of confluent C2C12 myoblasts
and NIH 3T3 cells with RAMP-1 promoter/luciferase deletion constructs revealed that 4.7 kb of
RAMP-1 5' flanking region demonstrated optimal promoter activity while 343 bp of 5' flanking
region was defined as a minimal RAMP-1 promoter. In non-RAMP-1 expressing HEK293 cells,
constructs containing 4.7 kb to 782 bp of RAMP-1 5' flanking region were transcriptionally inactive.
However, deletion of sequences -782 to -343 activated RAMP-1 promoter activity.
Conclusion: These findings suggest that tissue specificity of RAMP-1 gene expression is mediated
by a negative acting transcription factor that represses RAMP-1 gene expression in non-RAMP-1
expressing tissues. This transcription factor is therefore likely to play an important role in
modulating the responsiveness of tissues to CGRP.
Background
The calcitonin gene-related peptide (CGRP) belongs to a
family of related peptides that includes calcitonin (CT),
adrenomedullin (AM) and amylin (AMY) [1,2]. To date,
CGRP is one of the most potent endogenous vasodilatory
peptides discovered. CGRP mediates sensory neurotrans-
mission and inhibits insulin action on carbohydrate
metabolism [2]. CGRP has been shown to modulate
immune function by inhibiting the proliferation of T cells
and synthesis of T cell-derived cytokines IL-2 and IFN-γ  [3-
6]. In the lung, CGRP mediates multiple effects some of
which have potential implications in airway homeostasis
[7]. CGRP has also been shown to have cardioprotective
effects in rats and humans [8,9]. In skeletal muscle, CGRP
potentiates muscle contraction [10], increases the num-
bers of acetylcholine receptors (AchR) [11-13] and their
rate of desensitisation [14]. In addition, CGRP locally
increases the rate of blood flow following muscle contrac-
tion [15-17].
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The effects of CGRP are mediated by CGRP receptors that
are generated by a complex of proteins [18]. CGRP recep-
tors are formed by the interaction of two separate pro-
teins. The first protein component is the calcitonin
receptor like (CL) receptor. The CL receptor is a seven
transmembrane-domain receptor but is inactive when
expressed in cells alone [19]. The second protein compo-
nent required for CGRP receptor function is receptor activ-
ity modifying protein-1 (RAMP-1). RAMP-1 acts as a
molecular chaperone and is required for the transporta-
tion of the CL receptor to the cell surface in addition to
pharmacologic specificity [18].
RAMPs are a recently identified group of single transmem-
brane-domain accessory proteins. To date, three members
of the RAMP family have been identified (RAMP-1,
RAMP-2 and RAMP-3) [18]. All share 30% sequence iden-
tity, differ in their tissue distributions and are comprised
of approximately 160 amino acids that make up a large
extracellular N-terminal domain, a single membrane-
spanning domain and a short cytoplasmic domain
[18,20]. Recently, Christopoulos et al. [21] demonstrated
that RAMPS interact with a number of Class II G protein-
coupled receptors (GPCRs) in addition to the CL receptor.
These include the vasoactive intestinal polypeptide/pitui-
tary adenylate cyclase activating peptide receptor
(VPAC1R), the glucagon and parathyroid hormone recep-
tors (PTH1 and PTH2). VPAC1R/RAMP-2 heterodimers
display a significant enhancement of agonist-mediated
phosphoinositide hydrolysis compared with VPAC1R
alone. This suggests that RAMPs may play a more general
role in modulating cell signalling through other GPCRs
than previously thought.
Despite the crucial role RAMP-1 plays in the generation of
CGRP receptors, little is known about the molecular
mechanism(s) regulating RAMP-1 gene expression. It is
likely that such mechanism(s) play an important role in
modulating the responsiveness of specific tissues to
CGRP. To initiate studies on RAMP-1 gene regulation, we
cloned and characterised the mouse RAMP-1 gene pro-
moter. Analysis in three different RAMP-1 positive mouse
tissues revealed multiple start sites of transcription. RT-
PCR analysis of RAMP-1 mRNA in the C2C12 myoblast
cell line demonstrated that endogenous RAMP-1 gene
expression was greatest in confluent cultures compared to
non-confluent or fused cells. Through the use of RAMP-1
promoter/luciferase constructs transfected into C2C12
myoblast cells and NIH 3T3 cells, we studied the effects
RAMP-1 promoter deletions had on RAMP-1 transcrip-
tional activity. We further demonstrated that the RAMP-1
promoter activity was tissue-specific and not expressed in
the RAMP-1 negative cell line HEK293. Finally, we identi-
fied a repressor element in the RAMP-1 promoter which
when deleted activates RAMP-1 promoter activity in
HEK293 cells. This suggests the RAMP-1 gene is negatively
regulated in non-RAMP-1 expressing cells.
Results
Determination of RAMP-1 transcriptional initiation sites 
and PCR cloning the mouse RAMP-1 promoter
To date, the transcriptional initiation sites for any mouse
RAMP transcript have not yet been determined. We there-
fore performed 5' rapid amplification of cDNA ends
(RACE) analysis to map RAMP-1 transcriptional initiation
sites. For these experiments, RNA from a number of
known RAMP-1 positive mouse tissues (heart, brain and
skeletal muscle) was employed. Sequence analysis of 8–
10 5' RACE clones from each tissue demonstrated multi-
ple start sites of transcription (Table 1). All transcriptional
start sites in mouse heart, brain and skeletal muscle
occurred within a 50 bp region directly 5' to RAMP-1's
start site of translation. As demonstrated by the DNA
sequence analysis above, this region is highly GC rich
(78%). These results suggest that RAMP-1 transcriptional
initiation sites do not significantly vary between the dif-
ferent RAMP-1 positive tissues tested.
Having identified RAMP-1's major transcriptional initia-
tion sites, we next wished to clone and characterise the
mouse RAMP-1 gene promoter. Since extensive sequence
data both 5' and 3' to RAMP-1's transcriptional start sites
is available on the mouse genome data base (Accsession
no. NT_039173.2) we employed RAMP-1 specific primers
and PCR on mouse genomic DNA to generate a DNA frag-
ment containing 4.7 kb of RAMP-1 5' flanking region.
Promoter sequence motifs in the proximal 2.5 kb of 5'
Table 1: RAMP-1 5' RACE analysis. Total RNA was extracted 
from mouse brain, skeletal muscle and heart. RNA was treated 
with alkaline phosphatase, tobacco acid pyrophosphatase and 
ligated to a small adapter.  Following reverse transcription, 
multiple rounds of PCR were performed and the PCR products 
cloned and sequenced.  Transcriptional initiation sites are 
indicated relative to the start site of translation (ATG = 0). 
Mouse RAMP-1 transcriptional start sites
Clone Brain Muscle Heart
1- 4 1 - 5 0 - 4 1
2- 4 1 - 5 0 - 4 1
3- 4 1 - 4 0 - 4 1
4- 9 - 4 0 - 9
5- 9 - 5 0 - 3 5
6- 1 1 - 3 5 - 3 5
7 -50 -9 -9
8- 4 1 - 1 1 - 5 0
9- 5 0-- 4 1
10 -35 - -BMC Molecular Biology 2005, 6:7 http://www.biomedcentral.com/1471-2199/6/7
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flanking region corresponding to consensus binding sites
for a variety of transcription factors are present (Fig. 1).
These include binding sites for the transcription factors
NFκ B, PBX1, AML1, OCT1, MITF, TEF1 and Sp1. Of note
is a 147 bp region (-2188 to -2336) containing multiple
GAAA and GGAA repeat sequences and a highly GC rich
(78%) region of 144 bp region immediately 5' of the start
site of translation (ATG). This GC rich region contains a
potential binding site for the transcription factor Sp1.
RAMP-1 gene expression in C2C12 myoblasts and 
myotubes
Northern blot analysis has demonstrated that the RAMP-
1 gene is expressed in mouse skeletal muscle [20]. Since a
variety of muscle cell lines are widely available and are
easily transfected with DNA constructs, we decided to
employ such cell lines for our studies on the transcrip-
tional regulation of the mouse RAMP-1 gene. Before
undertaking transfection experiments in a muscle cell
line, we first studied endogenous RAMP-1 gene expression
in the myoblast cell line C2C12. Upon incubation with
reduced serum levels and high cell density, C2C12 myob-
lasts fuse and form myotubes. Pittner et al. [22] previously
demonstrated that incubation of this cell line with CGRP
induces an increase in intracellular levels of cAMP making
it highly likely this cell line expresses RAMP-1 mRNA. We
therefore assayed RAMP-1 gene expression in this cell line
by semi-quantitative RT-PCR analysis on total RNA from
non-confluent, confluent and fused C2C12 myoblasts.
Southern blot analysis of RT-PCR products from these
cells demonstrated the presence of RAMP-1 mRNA under
all culture conditions (Fig. 2). However, RAMP-1 mRNA
levels appeared to be highest in confluent versus non-con-
fluent and fused C2C12 myoblasts. Densitomitry demon-
strated that RAMP-1 mRNA expression was at least 6 times
higher in confluent vs. non-confluent myoblasts.
RAMP-1 promoter deletional analysis in transiently 
transfected C2C12 myoblasts
To delineate potential transcriptional regulatory elements
in the 4.7 kb RAMP-1 promoter, a series of 5' RAMP-1 pro-
moter/luciferase constructs were generated. Luciferase
analysis on transfected confluent C2C12 myoblasts
revealed that a RAMP-1 promoter/luciferase construct
with approximately 4.7 kb of 5' flanking region (relative
to RAMP-1's start site of translation) had the greatest lev-
els of luciferase activity (30 fold over the background plas-
mid pGL3 basic). Deletion of approximately 700 bp of 5'
flanking region (to -4102) caused up to a 55% drop in
expression levels. Deletions to -343 of RAMP-1 5' region
did not cause additional decreases in promoter activity.
However, deletion to -164 reduced RAMP-1 promoter
activity to 7-fold above background levels (Fig. 3). Similar
results were obtained when RAMP-1 promoter/lucifersase
constructs were transfected into RAMP-1 positive mouse
NIH 3T3 cells.
To determine if the RAMP-1 promoter demonstrates tis-
sue specificity in transfected cell lines, we compared the
transcriptional activity of the RAMP-1 promoter in trans-
fected C2C12 myoblasts and a cell line known to not
express RAMP-1 mRNA (HEK293). Luciferase analysis
demonstrated that constructs containing 4.7 kb to 782 bp
of RAMP-1 5' flanking region were transcriptionally inac-
tive in HEK293 cells. A construct containing 470 bp of
RAMP-1 5' flanking region demonstrated modest tran-
scriptional activity while a construct containing 343 bp of
5' flanking region demonstrated significant promoter
activity. The results of these experiments suggest that the
RAMP-1 promoter region between -782 and -343 contains
a regulatory element that represses RAMP-1 promoter
activity in a non-RAMP-1 expressing cell line.
Silencer activity of the RAMP-1 repressor element
We wished to determine if the RAMP-1 repressor element
could repress RAMP-1 promoter activity in a position and
orientation independent manner (silencer function). We
therefore employed PCR to generate a fragment (-343 to -
782 of the RAMP-1 promoter) containing the RAMP-1
repressor element. The fragment was then cloned in two
orientations 3' to the luciferase gene in the -343 RAMP-1
promoter/luciferase construct. The expression of these
constructs was compared to activity from the -343, -470
and -4724 RAMP-1 promoter/luciferase constructs in
transfected HEK293 cells. Luciferase assays demonstrated
that the repressor element reduced expression from the -
343 RAMP-1/luciferase construct by approximately 50%
(see Figure 4). An unpaired Student's t-test revealed that
these differences were statistically significant (p < .002
and p < .004 for 5'-3' and 3'-5' silencer constructs, respec-
tively). However, these constructs demonstrated signifi-
cantly higher levels of activity than the -470 RAMP-1/
luciferase construct (p < .006 and p < .003 for 5'-3' and 3'-
5' silencer constructs, respectively). These results suggest
that the RAMP-1 repressor element located between -343
and -782 bp of RAMP-1 5' flanking region has modest but
statistically significant silencer activity and functions best
in its native position.
Discussion
Despite the important role RAMP-1 plays in CGRP cell sig-
nalling little is known about the transcriptional regulation
of RAMP-1 gene. To date, no RAMP-1 gene promoter has
been identified/cloned and RAMP-1 transcriptional initi-
ation sites have not been determined in any RAMP-1 pos-
itive tissues. In the present study, we cloned the mouse
RAMP-1 gene promoter and mapped multiple RAMP-1
transcriptional initiation sites in a variety of RAMP-1 pos-
itive tissues. Our data demonstrates that RAMP-1 tran-BMC Molecular Biology 2005, 6:7 http://www.biomedcentral.com/1471-2199/6/7
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DNA sequence of mouse RAMP-1 5' flanking region Figure 1
DNA sequence of mouse RAMP-1 5' flanking region. Potential transcription factor binding sites have been underlined. Under-
lined ATG sequence is start site of translation = 0. Transcriptional initiation sites mapped by 5' RACE analysis are indicated by 
*asterisks.BMC Molecular Biology 2005, 6:7 http://www.biomedcentral.com/1471-2199/6/7
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scriptional initiation occurs at similar sites and all within
a 50 bp region in different RAMP-1 mRNA positive
tissues.
To initiate studies on the transcriptional regulation of the
mouse RAMP-1 gene during muscle differentiation, we
examined RAMP-1 gene expression in C2C12 mouse
myoblasts by semi-quantitative RT-PCR. Our results sug-
gest that RAMP-1 gene expression is present in non-con-
fluent, confluent and fused C2C12 cells. However RAMP-
1 mRNA expression appears to be increased in confluent
and fused C2C12 cells. Chakravarty et al. [23] demon-
strated that a strong correlation exists between the level of
RAMP-1 mRNA expression and CGRP binding. This sug-
gests that the transcriptional activity of the RAMP-1 gene
may control the responsiveness of tissues to CGRP. It will
be important to determine if increased RAMP-1 mRNA
expression in confluent and fused C2C12 cells results in
significantly higher levels of CGRP receptor expression
and increases in intracellular cAMP after treatment with
CGRP. The role increased RAMP-1 mRNA gene expression
plays in the process of C2C12 induced muscle differentia-
tion is not yet clear. Nobel et al. [24] showed that CGRP
causes increased creatine kinase activity in myoblast
cultures. Creatine kinase activity is a well established
marker of fused myoblasts (myotubes). It is reasonable to
hypothesise that increased RAMP-1 gene expression in
confluent C2C12s makes these cells more responsive to
CGRP and thus may facilitate myoblast fusion.
Deletional mapping of the RAMP-1 gene promoter
revealed that a 4.7 kb promoter fragment generates the
highest levels of RAMP-1 promoter activity. However, a
RAMP-1 promoter construct with only 343 bp of 5' region
contains nearly 40% percent activity of the entire pro-
moter. The delineation of such a small functional RAMP-
1 promoter should facilitate the identification of DNA
regulatory elements and the transcription factors they
interact that activate RAMP-1 promoter activity in C2C12
cells.
Transfection of RAMP-1 promoter/luciferase constructs
into RAMP-1 negative HEK293 cells demonstrated that a
transcriptional control element present between -782 and
-343 in the RAMP-1 promoter represses RAMP-1 pro-
moter activity in the RAMP-1 negative-expressing cell line
HEK293 cells. While this element appears to have modest
silencing activity, our results suggest that full repressor
activity of this element requires it to be in its native posi-
tion within the RAMP-1 promoter. We hypothesise that
negative-regulatory transcription factors, present in non-
RAMP-1 expressing cells, bind to this element and repress
RAMP-1 gene expression. Computer analysis of the 480
bp RAMP-1 repressor element has revealed potential
binding sites for a variety of positive acting transcription
factors such as MyoD, c-Myb, NF1 and Elk-1. Importantly,
binding sites for two transcriptional repressors have also
been identified: mammalian transcriptional repressor
RBPJkappa/CBF (RBPJK) and bZIP domain, transcrip-
tional repressor (E4BP4). Studies on the roles these tran-
scription factors play in the repression of RAMP-1 gene
expression are now underway.
Conclusion
Promoter deletional analysis demonstrated that both pos-
itive and negative acting transcription factors regulate the
tissue specificity of the RAMP-1 gene. DNase 1 protection
and gel-shift experiments with extracts from C2C12 and
HEK293 cells are underway to identify specific DNA
sequences and the potential transcription factors they
bind that mediate the activity of the RAMP-1 gene in
RAMP-1 expressing and non- expressing cells. Once spe-
cific sequences/factors binding to the RAMP-1 repressor
element are isolated, the effects that mutating these
sequences has on RAMP-1 promoter activity in transgenic
mice will be tested. These experiments will enable us to
test the role such sequences/factors play in regulating the
tissue-specific expression and activity levels of the RAMP-
1 gene in vivo. Such transcriptional mechanism(s) are
likely to play an important role in modulating the respon-
Semi-quantitative RT-PCR on RAMP-1 gene expression in  C2C12 cells Figure 2
Semi-quantitative RT-PCR on RAMP-1 gene expression in 
C2C12 cells. Total RNA was isolated from C2C12 non-con-
fluent cells (nc), confluent (c) and myotubes (mt). The RNA 
was subjected to reverse transcription followed by PCR with 
mouse RAMP-1 and actin specific primers. The PCR reac-
tions were stopped after 30, 35, 40 cycles and size fraction-
ated on a 1% agarose gel. The DNA was then Southern 
blotted overnight and hybridised with a 32P end-labelled 
RAMP-1 and actin specific probes followed by autoradiogra-
phy. This experiment is representative of three experiments 
each giving similar results.BMC Molecular Biology 2005, 6:7 http://www.biomedcentral.com/1471-2199/6/7
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siveness of tissues to CGRP and may prove useful targets
for future drug development aimed at regulating CGRP
receptor gene expression.
Methods
5' RACE analysis
5' RACE on total RNA from mouse heart, skeletal muscle
and brain was performed employing a First Choice RLM-
RACE kit (Ambion) according to manufacturers instruc-
tions. Briefly, 10 µg of total RNA from each tissue was
treated with Calf Intestine Alkaline Phosphatase (CIP) for
one hour at 37°C followed by extraction with phe-
nol:chloroform and ethanol precipitation. The RNA was
re-suspended in 11 µl of H20. 5 µl of this RNA was then
treated with tobacco acid pyrophosphate (TAP) for one-
hour at 37°C. A 5' RACE adapter (provided in kit) was
ligated to 5 µl of the TAP treated RNA. 2 µl of ligated RNA
was subjected to reverse transcription (RT). RT products (1
µl) were subjected to two rounds of nested PCR according
to manufacturers instructions. The first round of PCR
employed an outer primer binding to the 5' RACE adapter
(5'GCTGATGGCGATGAATGAACACTG 3') and an outer
RAMP-1 gene specific primer (5' CGGGACCCTGACTAT-
GGGAC 3'). The second round of PCR employed an inner
primer binding to the 5' RACE adapter (5'GCTGAT-
GGCGATGAATGAACACTG 3') and an inner RAMP-1
gene specific primer (5' TCTTCATGGTCACTGCCTGC 3').
Following the second round of PCR, PCR products were
RAMP-1 promoter/luciferase activity in RAMP-1 positive and negative cell lines Figure 3
RAMP-1 promoter/luciferase activity in RAMP-1 positive and negative cell lines. RAMP-1 promoter-deletion constructs were 
generated by PCR and ligated into the luciferase expression vector pGL3-basic. The amount of 5' flanking region relative to the 
start site of translation (ATG = 0) is indicated for each construct. Constructs were transiently transfected into RAMP-1 posi-
tive expressing cells (C2C12 and NIH3T3) and RAMP-1 negative cells (HEK293). Forty-eight hours after transfection, cells 
were harvested and assayed for luciferase activity. The co-transfection control plasmid pRL-TK was employed for all transfec-
tions. Relative luciferase activities were determined by comparing luciferase activity of cells transfected with RAMP-1/luciferase 
deletion constructs to cells transfected with the promoterless pGL3-basic plasmid. Background levels of luciferase = 1. The 
data are an average of three independent sets of transfections each giving similar results.BMC Molecular Biology 2005, 6:7 http://www.biomedcentral.com/1471-2199/6/7
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purified on an agarose gel and ligated into the PCR clon-
ing vector pGEM-T Easy (Promega). A total of 8–10 clones
representing each tissue were purified and subjected to
DNA sequencing.
Generation of RAMP-1 promoter/luciferase expression 
constructs
To generate RAMP-1 promoter/luciferase deletion con-
structs, PCR utilising an antisense primer corresponding
to sequences -26 to -43 (see Fig. 1) and sense primers cor-
responding to -145 to -164; -324 to -343; -470 to -450; -
760 to -782; -935 to -948; -1220 to -1243; -1574 to -1593;
-1827 to -1846; -2032 to -2093; -2342 to -2365; -2533 to
-2511; -4102 to -4079 and -4724 to -4702 was carried out
as described in Jagger et al. [25]. The PCR fragments were
cloned into the vector pGEM-T Easy (Promega) and
sequenced. The plasmids were then cut with Not 1 and the
released RAMP-1 promoter fragment filled in with Kle-
now, purified and cloned into the luciferase expression
vector pGL3 basic (Promega).
To generate a construct containing the RAMP-1 repressor
element cloned at the 3' end of the luciferase gene, the
RAMP-1 promoter/luciferase construct containing 343 bp
of 5' flanking region was cut with Bam H1. A region
between -343 and -782 of the mouse RAMP-1 promoter
was generated by PCR as above and cloned into the Bam
H1 cut -343 RAMP-1 promoter/luciferase construct in two
orientations.
Tissue culture and RAMP-1/luciferase transfections
C2C12, HEK293 and NIH 3T3 cells were maintained in
DMEM supplemented with 10% foetal calf serum, 100
µg/ml penicillin and 100 U/ml of streptomycin. To gener-
ate fused C2C12 myotubes, cells were allowed to become
confluent and growth media was replaced with media
Silencer activity of RAMP-1 repressor element in transfected HEK293 cells Figure 4
Silencer activity of RAMP-1 repressor element in transfected HEK293 cells. A RAMP-1 repressor element fragment (-783 to -
343) was generated by PCR and ligated directly 3' to the luciferase gene in the RAMP-1 expression plasmid -343 RAMP-1/luci-
ferase. The fragment was oriented in two different positions (5' to 3' and 3' to 5'). Relative luciferase activity was compared 
between these constructs, pGL3-basic, a plasmid containing 470 and 4.7 kb of RAMP-1 5' flanking region. Three independent 
sets of transfections were performed each giving similar resultsBMC Molecular Biology 2005, 6:7 http://www.biomedcentral.com/1471-2199/6/7
Page 8 of 8
(page number not for citation purposes)
containing only 1% foetal calf serum. For transient trans-
fections in all the above cell lines, cells were transfected
with 1.0–1.5 µg of specific RAMP-1/luciferase construct,
0.2  µg of a co-transfection control plasmid pRLTK
(Promega) and Fugene 6 (Roche) according to
manufacturers' instructions. Luciferase assays were per-
formed employing a Dual Luciferase Reporter Assay Sys-
tem (Promega) and a Turner Design TD-20/20
luminometer.
Semi-quantitative RT-PCR on RAMP-1 mRNA in 
differentiating C2C12 myoblasts
Total RNA from non-confluent, confluent and fused
C2C12 myoblasts was isolated as above and reverse tran-
scriptase (RT) reactions performed as previously described
[25]. PCR amplification employing mouse RAMP-1 sense
(5' CTATGGGGAGCTCACTTACTGC 3') and antisense
(5'GCAGTCTTCCTTGGAGTTCAGAAT 3') oligos; mouse
actin sense (5'GTTAACCAACTGGGACGACATGG 3') and
anti-sense (5'GATCTTGATCTTCATGGTGC 3') mouse
actin primers was performed as previously described [26].
A total of 30, 35 and 40 cycles were employed. The PCR
products were run on a 1% agarose gel and Southern blot-
ted to nylon membranes. The blots were probed with an
end-labelled  32P actin probe (5'
CACACTGTGCCCATCTACGA3') or RAMP-1 probe
(5'GCCCAATCCGGAAGTGGACA 3') followed by autora-
diography and densitomitry.
Abbreviations
CGRP, calcitonin gene related peptide; CTR, calcitonin
receptor; RAMP, receptor activity modifying protein;
GPCR, G protein coupled receptor; CL, calcitonin receptor
like
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